|
JPS6041077B2
(ja)
|
1976-09-06 |
1985-09-13 |
喜徳 喜谷 |
１，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
|
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
|
US5266573A
(en)
|
1989-08-07 |
1993-11-30 |
Elf Sanofi |
Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
ATE446955T1
(de)
|
1995-03-30 |
2009-11-15 |
Pfizer Prod Inc |
Chinazolinone derivate
|
|
US5763263A
(en)
|
1995-11-27 |
1998-06-09 |
Dehlinger; Peter J. |
Method and apparatus for producing position addressable combinatorial libraries
|
|
CN100503580C
(zh)
|
1996-04-12 |
2009-06-24 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂
|
|
ZA986732B
(en)
|
1997-07-29 |
1999-02-02 |
Warner Lambert Co |
Irreversible inhibitiors of tyrosine kinases
|
|
TW436485B
(en)
|
1997-08-01 |
2001-05-28 |
American Cyanamid Co |
Substituted quinazoline derivatives
|
|
JP3270834B2
(ja)
|
1999-01-27 |
2002-04-02 |
ファイザー・プロダクツ・インク |
抗がん剤として有用なヘテロ芳香族二環式誘導体
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
EE05345B1
(et)
|
1999-02-10 |
2010-10-15 |
Astrazeneca Ab |
Kinasoliini derivaadid angiogeneesi inhibiitoritena
|
|
NZ516633A
(en)
|
1999-06-21 |
2004-09-24 |
Boehringer Ingelheim Pharma |
Bicyclic heterocycles, medicaments containing these compounds, their use and methods for the production thereof
|
|
PE20010306A1
(es)
|
1999-07-02 |
2001-03-29 |
Agouron Pharma |
Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
|
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
DE50111799D1
(de)
|
2000-04-08 |
2007-02-15 |
Boehringer Ingelheim Pharma |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
DE10042061A1
(de)
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
KR100600550B1
(ko)
|
2000-10-20 |
2006-07-13 |
에자이 가부시키가이샤 |
질소 함유 방향환 유도체
|
|
DE10063435A1
(de)
|
2000-12-20 |
2002-07-04 |
Boehringer Ingelheim Pharma |
Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
JP4285996B2
(ja)
*
|
2001-02-21 |
2009-06-24 |
田辺三菱製薬株式会社 |
キナゾリン誘導体
|
|
ES2263743T3
(es)
|
2001-04-13 |
2006-12-16 |
Pfizer Products Inc. |
Derivados de 4-aminopiridopirimidina sustituidos con un grupo biciclico.
|
|
DE60223279T2
(de)
|
2001-11-30 |
2008-05-29 |
Osi Pharmaceuticals, Inc. |
Verfahren für die herstellung substituierter bicyclischer derivate zur behandlung von anomalem zellwachstum
|
|
EP1478648B1
(en)
|
2002-02-01 |
2014-04-30 |
ARIAD Pharmaceuticals, Inc. |
Phosphorus-containing compounds and uses thereof
|
|
RU2312861C2
(ru)
|
2002-03-05 |
2007-12-20 |
Мерк Фросст Кэнада Лтд. |
Ингибиторы катепсин-цистеинпротеазы
|
|
DE10217689A1
(de)
|
2002-04-19 |
2003-11-13 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
PE20040945A1
(es)
|
2003-02-05 |
2004-12-14 |
Warner Lambert Co |
Preparacion de quinazolinas substituidas
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
BRPI0414488A
(pt)
|
2003-09-16 |
2006-11-14 |
Astrazeneca Ab |
derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, métodos para produzir um efeito anti - proliferativo em um animal de sangue quente, para prevenção ou tratamento de tumores em um aminal de sangue quente, para fornecer um efeito inibidor da tirosina quinase de egfr seletivo em um animal de sangue quente e para tratar um cáncer em um animal de sangue quente e, processo para a preparação de um derivado de quinazolina
|
|
HRP20110958T1
(hr)
|
2004-05-06 |
2012-01-31 |
Warner-Lambert Company Llc |
4-fenilaminokinazolin-6-ilamidi
|
|
JPWO2006025490A1
(ja)
*
|
2004-09-01 |
2008-05-08 |
田辺三菱製薬株式会社 |
分子シャペロン機能調節剤
|
|
WO2006028958A2
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Pyridyl inhibitors of hedgehog signalling
|
|
NZ556673A
(en)
|
2005-02-03 |
2010-03-26 |
Gen Hospital Corp |
Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
PE20070207A1
(es)
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
WO2007055513A1
(en)
|
2005-11-08 |
2007-05-18 |
Hanmi Pharm. Co., Ltd. |
Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
|
|
KR100832593B1
(ko)
|
2005-11-08 |
2008-05-27 |
한미약품 주식회사 |
신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
|
|
KR20080015594A
(ko)
|
2006-08-16 |
2008-02-20 |
주식회사종근당 |
포스포디에스테라제 저해제로서 유용한 퀴나졸린 유도체 및그 제조방법
|
|
CA2662617C
(en)
|
2006-09-11 |
2014-11-18 |
Changgeng Qian |
Quinazoline based egfr inhibitors containing a zinc binding moiety
|
|
TWI377944B
(en)
|
2007-06-05 |
2012-12-01 |
Hanmi Holdings Co Ltd |
Novel amide derivative for inhibiting the growth of cancer cells
|
|
WO2008157500A1
(en)
|
2007-06-17 |
2008-12-24 |
Kalypsys, Inc. |
Aminoquinazoline cannabinoid receptor modulators for treatment of disease
|
|
BRPI0816769A2
(pt)
|
2007-09-12 |
2016-11-29 |
Hoffmann La Roche |
combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
|
|
WO2009055730A1
(en)
|
2007-10-25 |
2009-04-30 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
US9006252B2
(en)
|
2008-09-26 |
2015-04-14 |
National Health Research Institutes |
Fused multicyclic compounds as protein kinase inhibitors
|
|
CA2804190A1
(en)
|
2009-07-02 |
2011-01-06 |
Newgen Therapeutics, Inc. |
Phosphorus containing quinazoline compounds and methods of use
|
|
US8735409B2
(en)
|
2009-12-21 |
2014-05-27 |
Qiang Zhang |
Quinazoline derivatives
|
|
CN102382106A
(zh)
|
2010-08-30 |
2012-03-21 |
黄振华 |
苯胺取代的喹唑啉衍生物
|
|
CN102382065B
(zh)
|
2010-08-30 |
2014-05-28 |
山东轩竹医药科技有限公司 |
苯胺取代的喹唑啉衍生物
|
|
CN102452989B
(zh)
|
2010-10-19 |
2014-10-22 |
山东轩竹医药科技有限公司 |
苯胺取代的喹唑啉衍生物
|
|
EP2680850B1
(en)
*
|
2011-03-04 |
2018-05-23 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compound and methods of use
|
|
CN102731485B
(zh)
|
2011-04-02 |
2016-06-15 |
齐鲁制药有限公司 |
4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
|
|
CN102918029B
(zh)
|
2011-05-17 |
2015-06-17 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
|
TWI577693B
(zh)
|
2011-05-31 |
2017-04-11 |
江蘇康緣藥業股份有限公司 |
聚（ａｄｐ-核糖）聚合酶之三環抑制劑
|
|
CA2841932A1
(en)
|
2011-07-13 |
2013-01-17 |
Novartis Ag |
4 - piperidinyl compounds for use as tankyrase inhibitors
|
|
CN102898386B
(zh)
|
2011-07-27 |
2015-07-29 |
上海医药集团股份有限公司 |
喹唑啉衍生物、其制备方法、中间体、组合物及其应用
|
|
CN102516232A
(zh)
|
2011-12-14 |
2012-06-27 |
无锡美克赛医药科技有限公司 |
一种ErbB2的小分子选择性抑制剂及其应用
|
|
CN103987700B
(zh)
|
2012-03-09 |
2016-08-31 |
江苏豪森药业集团有限公司 |
4-喹唑啉胺类衍生物及其用途
|
|
WO2013173254A1
(en)
|
2012-05-14 |
2013-11-21 |
Dawei Zhang |
Bicyclic compounds as kinases inhibitors
|
|
CA2876689C
(en)
*
|
2012-06-13 |
2022-04-26 |
Incyte Corporation |
Substituted tricyclic compounds as fgfr inhibitors
|
|
CN102942561A
(zh)
|
2012-11-06 |
2013-02-27 |
深圳海王药业有限公司 |
4-氨基喹唑啉杂环化合物及其用途
|
|
CN103965120B
(zh)
|
2013-01-25 |
2016-08-17 |
上海医药集团股份有限公司 |
喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
|
|
CN104119350B
(zh)
|
2013-04-28 |
2017-04-12 |
广东东阳光药业有限公司 |
氨基喹唑啉类衍生物及其盐和使用方法
|
|
CN104513229A
(zh)
|
2013-09-28 |
2015-04-15 |
正大天晴药业集团股份有限公司 |
喹唑啉衍生物及其制备方法
|
|
MX380928B
(es)
|
2013-10-10 |
2025-03-12 |
Araxes Pharma Llc |
Inhibidores de kras g12c.
|
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
|
WO2016023217A1
(zh)
|
2014-08-15 |
2016-02-18 |
安润医药科技（苏州）有限公司 |
喹唑啉衍生物、其制备方法、药物组合物和应用
|
|
WO2016055982A1
(en)
|
2014-10-10 |
2016-04-14 |
Acerta Pharma B.V. |
Quinoline and quinazoline compounds
|
|
HRP20230305T1
(hr)
|
2014-12-24 |
2023-05-26 |
Principia Biopharma Inc. |
Pripravci za ileo-jejunalnu dostavu lijeka
|
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
US9890187B2
(en)
|
2015-06-26 |
2018-02-13 |
Epos-Iasis Research And Development, Ltd. |
Prototype systems of theranostic biomarkers for in vivo molecular management of cancer
|
|
GB201517216D0
(en)
|
2015-09-29 |
2015-11-11 |
Cancer Res Technology Ltd And Astex Therapeutics Ltd |
Pharmaceutical compounds
|
|
WO2017112777A1
(en)
|
2015-12-22 |
2017-06-29 |
SHY Therapeutics LLC |
Compounds for the treatment of cancer and inflammatory disease
|
|
CN105348271A
(zh)
|
2015-12-23 |
2016-02-24 |
常州润诺生物科技有限公司 |
喹唑啉类衍生物药用用途及其制备方法
|
|
EP3856349A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
WO2020068867A1
(en)
|
2018-09-25 |
2020-04-02 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
|
|
CN109265449B
(zh)
|
2018-11-07 |
2021-11-23 |
沈阳工业大学 |
Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
|
|
WO2020139748A1
(en)
|
2018-12-28 |
2020-07-02 |
Cedars-Sinai Medical Center |
Methods of treating inflammatory bowel diseases that target ripk2
|
|
AU2020328598B2
(en)
|
2019-08-15 |
2026-07-02 |
Black Diamond Therapeutics, Inc. |
Alkynyl quinazoline compounds
|
|
EP4097083A1
(en)
|
2020-01-29 |
2022-12-07 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of apol1 and methods of using same
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
US11608343B2
(en)
|
2020-04-24 |
2023-03-21 |
Boehringer Ingelheim International Gmbh |
Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
|
|
WO2022040377A1
(en)
|
2020-08-20 |
2022-02-24 |
Black Diamond Therapeutics, Inc. |
Methods for preparing quinazoline derivatives
|
|
WO2022076671A1
(en)
|
2020-10-08 |
2022-04-14 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers using quinazoline derivatives
|
|
MX2023004998A
(es)
|
2020-11-02 |
2023-05-12 |
Black Diamond Therapeutics Inc |
Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.
|
|
WO2023049168A1
(en)
|
2021-09-21 |
2023-03-30 |
Black Diamond Therapeutics, Inc. |
Polymorphs as erbb inhibitors
|
|
WO2025038731A1
(en)
|
2023-08-15 |
2025-02-20 |
Black Diamond Therapeutics, Inc. |
Method of treating cancers with alkyne substituted quinazoline derivatives
|